Ponatinib, bosutinib, and repotrectinib are FDA-approved for the treatment of acute lymphoblastic leukemia, childhood chronic myeloid leukemia, and ROS1-positive non-small cell lung cancer, respectively. The gene discussed is ROS1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.